MBX
MBX BiosciencesN/ANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Positive clinical or regulatory outcomes plus a partnership/licensing deal would re-rate the stock; partnership proceeds and reduced dilution support the >50% upside implied by the bull target.
Posture
Unrated
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +9.2.
What can break
Clinical setbacks, missed guidance, or dilutive financing would likely trigger sharp declines, consistent with the >30% downside implied by the bear target.
Momentum
68
Value
N/A
Sentiment
73
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $37.94 · Bull $51.74 · Bear $24.14
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-29 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade N/A · Unrated
Confidence Medium · Net Neutral
Target $61.10
Why
Momentum68 · Δ7d -6.2
ValueN/A · Δ7d -
Sentiment73 · Δ7d +9.2
So what
Insufficient data coverage. Recheck when scores populate.
Lead driver: Sentiment · See AI snapshot
Momentum
68
51% active weight
Current posture
7d trendSoftening
Δ7d
-6.2
Δ21d
-4.4
Value
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Sentiment
73
49% active weight
Current posture
7d trendImproving
Δ7d
+9.2
Δ21d
+37.8
Why this grade
No composite grade available (requires momentum and value).
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$1.46B
Beta
-
Shares Out
33.42M
P/E (TTM) · Derived
-23.6
P/S (TTM)
-
P/FCF (TTM)
-
Rev YoY
-
EPS YoY
-
Gross Margin
-
Op Margin
-
Net Debt
-
Current Ratio
-
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology